Denosumab - Osteoporosis
You are here : Home > Formulary Search > Denosumab - Osteoporosis
Status 1
- Subcutaneous injection (sc)
Documentation
PAD Profile
Rheumatology only in secondary care.
Restricted to use in patients for whom bisphosphonates are unsuitable.
Other Indications
Below are listed other indications that Denosumab is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Osteoporosis.
Committee Recommendations (3)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed Denosumab Prescribing Information to support initiation and ongoing administration in primary care.
Patient Specific Directions (PSDs) are often used to enable non-medical practitioners (practice nurses, health care assistants) to administer specific medicines for specific conditions. A PSD tempate for EMIS system users has been developed by a local GP practice to improve the consistency and content of their Denosumab PSDs. This PSD template (among others) is available from your local Medicines Management Team should your practice wish to adopt / adapt it. Please contact your local Medicines Management Team for assistance
Denosumab has been included as a treatment option for postmenopausal women and men who are intolerant to two bisphosphonates / or have a contraindication to bisphosphonates.
Certain patients should remain under the care of the secondary care clinicians and they include: Renal patients with a CKD of 4 or 5 and patients with a T score of <-4.5.
The osteoporosis guidelines are supported by two algorithms (algorithm 1 - Treatment Pathway for adults; algorithm 2 - Review of Long-term Bisphosphonate Therapy) which have been extracted from the guideline and provided as separate documents (below) for ease of use.